Promoting Competition
and Investment in the
U.S. Life Sciences Ecosystem
The U.S. life sciences ecosystem depends on mergers and acquisitions (M&A) to bring together the resources, investment and expertise needed to develop and deliver new treatments and cures for patients.
PARTNERS
ABOUT US
PULSE is dedicated to raising awareness about the vital role of mergers and acquisitions (M&A) as well as other collaborations to bring together the resources, investment and expertise needed to develop and deliver new treatments and cures for patients. Our members represent frontline researchers, employees and leaders of life sciences companies of all sizes that support a diverse, vibrant life sciences ecosystem at the national level and in local communities. PULSE will help advance a national dialogue focused on fostering innovation across the life sciences while supporting a competitive U.S. market that delivers next generation treatments and cures
for patients.
LATEST NEWS
General Catalyst: Pro-Competitive Partnerships Drive “Steady Drumbeat of Innovation” in the Life Sciences
Investment in early-stage life sciences companies is critical to sustain America’s global leadership in discovering and developing new medical breakthroughs for patients, according to a recent General Catalyst blog, “The Future of Life Sciences Investment.”
Innovations Advanced by M&A: A New Therapy for Ulcerative Colitis
The acquisition of Arena Pharmaceuticals by Pfizer in 2022 enabled the development and commercialization of Velsipity (etrasimod), an innovative therapy for moderate to severe ulcerative colitis (UC).
NYU Law Review: Antitrust Overreach Risks Chilling Investment in Early-Stage Innovations
In their recent New York University Law Review article, “No Exit,” Matthew Wansley and Samuel Weinstein discuss how the Federal Trade Commission (FTC) and Department of Justice (DOJ)’s approach toward M&A is obstructing a critical exit point for innovative early-stage companies.